Medicine and Dentistry
B Cell
12%
Biological Marker
15%
Biopsy
45%
Breast Cancer
70%
Breast Carcinoma
9%
Carcinoma
9%
Cetuximab
10%
Diagnosis
23%
Disease
17%
Epidermal Growth Factor Receptor
15%
Epidermal Growth Factor Receptor 2
15%
Estrogen Receptor
18%
Gamma Urogastrone
18%
Germinal Center
14%
Gland Tissue
11%
Hazard Ratio
13%
Head and Neck Cancer
16%
Head and Neck Squamous Cell Carcinoma
27%
Histopathology
19%
Image Analysis
14%
Imaging Agent
10%
Immunohistochemistry
28%
Intraductal Carcinoma
13%
Laryngeal Cancer
9%
Lymph Node
11%
Lymph Node Metastasis
11%
Macrophage
14%
Malignant Neoplasm
36%
Metastatic Breast Cancer
14%
Metastatic Carcinoma
18%
Molecular Imaging
14%
Mouth Squamous Cell Carcinoma
26%
Narrow Band Imaging
9%
Neck
23%
Neoplasm
100%
Oral Cancer
19%
Parotid Gland
28%
Positron Emission Tomography
13%
Radiation Therapy
9%
Receptor Expression
12%
Recurrent Disease
23%
Salivary Gland
40%
Salivary Gland Biopsy
10%
Sentinel Lymph Node Biopsy
9%
Sjoegren Syndrome
34%
Specific Tumor
10%
Squamous Cell Carcinoma
9%
Surgical Margin
18%
Systematic Review
12%
Tissue Microarray
9%
Keyphrases
18F-FES PET
6%
Abatacept
9%
B Lymphocytes
5%
Breast Cancer
11%
CGAS-STING
6%
Clinical Data
6%
Clinical Outcomes
6%
Confidence Interval
8%
Digital Image Analysis
9%
Disease-specific Mortality
5%
DNA Methyltransferase 1 (DNMT1)
6%
Epidermal Growth Factor Receptor
11%
Estrogen Receptor Status
6%
Fluorescent Tracer
5%
Focus Measure
5%
Germinal Center
14%
GPNMB
6%
Hazard Ratio
10%
Head-and-neck Cancer
9%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
18%
High Risk
8%
Histopathological Features
7%
Human Epidermal Growth Factor Receptor 2 (HER2)
9%
Human Epidermal Growth Factor Receptor 2-negative
6%
Imaging Target
7%
Immunohistochemistry
11%
Invasive Ductal Breast Carcinoma
6%
Ki-67
5%
Laryngeal Squamous Cell Carcinoma
7%
Local Recurrence
6%
Locally Advanced
6%
Lymph Node Metastasis
5%
Lymphoepithelial Lesion
5%
Metastasis
8%
Metastatic Breast Cancer
6%
Minor Salivary Gland Biopsy
10%
Netherlands
5%
Oral Tongue Squamous Cell Carcinoma (OTSCC)
9%
Overall Survival
6%
Parotid
11%
Parotid Gland
14%
Primary Sjgren's Syndrome
24%
Primary Sjögren's Syndrome
26%
Primary Tumor
7%
Risk-reducing Salpingo-oophorectomy
6%
Salivary Gland
9%
Sjgren's Syndrome
6%
Tumor
8%
Tumor Characteristics
7%
Tumor Microenvironment
6%